Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPJKRL)

• Drug Name: BITHIONOL Drug Info
• Synonyms: bithionol; 97-18-7; Actamer; Bithin; 2,2'-Thiobis(4,6-dichlorophenol); Lorothidol; Bitionol; Bithionol sulfide; Bisoxyphen; Bidiphen; Lorothiodol; Bitin; Nobacter; Bithionolate; Neopellis; Vancide BL; Usaf B-22; Bithional; Bithionolum; 2-Hydroxy-3,5-dichlorophenyl sulfide; TKhsd; Bis(2-hydroxy-3,5-dichlorophenyl) sulfide; Bis(3,5-dichloro-2-hydroxyphenyl) sulfide; 2,2'-sulfanediylbis(4,6-dichlorophenol); Caswell No. 852; Bitionol [INN-Spanish]; XL 7; Bithionolum [INN-Latin]; 2,2'-Dihydroxy-3,3',5,5'-tetrachlorodiphenyl sulfide

Indication

Disease Entry	ICD 11	Status	REF
Trematode infection	1F8Y	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 2406
  ChEBI ID: CHEBI:3131
  CAS Number: CAS 97-18-7
  TTD Drug ID: DMPJKRL
  VARIDT Drug ID: DR00936

Molecule-Related Drug Atlas

Drug(s) Targeting Calpain-2 (CAPN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-957	DMB9N4J	Alzheimer disease	8A20	Phase 1	[4]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[5]
Epoxysuccinate derivative 9	DM49FU0	N. A.	N. A.	Patented	[5]
Epoxysuccinate derivative 4	DMCF6M8	N. A.	N. A.	Patented	[5]
Carboxamide derivative 7	DM8TQS4	N. A.	N. A.	Patented	[5]
Epoxysuccinate derivative 7	DMTSPVF	N. A.	N. A.	Patented	[5]
Carboxamide derivative 10	DM5WMO9	N. A.	N. A.	Patented	[5]
Carboxamide derivative 11	DM1DN94	N. A.	N. A.	Patented	[5]
Carboxamide derivative 8	DM6HI34	N. A.	N. A.	Patented	[5]
Epoxysuccinate derivative 10	DMYF39U	N. A.	N. A.	Patented	[5]

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[7]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[7]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[8]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[9]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[10]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[11]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[12]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[12]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[12]

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated Estrogens	DMLT0E1	Dyspareunia	GA12	Approved	[13]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[14]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[15]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[16]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[17]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[18]
AUS-131	DMUXO3Z	Hot flushes	GA30	Phase 2	[19]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[20]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[21]
VG-101	DMAN21O	Menopause symptom	GA30.0	Phase 1/2	[22]

Drug(s) Targeting Estrogen receptor (ESR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[24]
Estradiol Valerate	DM8MC6O	Hormone replacement therapy	8E01	Approved	[14]
Estradiol Acetate	DM07U2A	Hormone replacement therapy	8E01	Approved	[14]
Estradiol Cypionate	DM27Z5T	Hormone replacement therapy	8E01	Approved	[14]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[25]
Raloxifene	DMDKF3M	Osteoporosis	FB83.0	Approved	[26]
Ospemifene	DMC4GEI	Dyspareunia	GA12	Approved	[27]
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[28]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[30]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[33]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[34]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[35]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[37]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calpain-2 (CAPN2)	TTG5QB7	CAN2_HUMAN	Inhibitor	[2]
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Inhibitor	[2]
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[2]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2338).
• [2] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [3] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
• [6] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Prelude Therapeutics.
• [9] Clinical pipeline report, company report or official report of AbbVie.
• [10] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
• [11] Clinical pipeline report, company report or official report of Amgen.
• [12] Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
• [13] Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
• [16] Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
• [17] MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
• [18] Company report (Axcentua)
• [19] S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
• [20] Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
• [22] Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.
• [23] Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
• [24] Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
• [25] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [27] Clinical pipeline report, company report or official report of Shionogi (2011).
• [28] Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
• [29] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [30] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [31] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [32] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [33] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [34] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [35] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [36] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [37] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [38] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.